#AbbVie

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

In an analysis of the investigational treatment, cure rates were very high for those without cirrhosis after both 8 and 12 weeks of therapy.

The recent trial of glecaprevir/pibrentasvir included those with genotypes 1, 2, 4, 5 and 6 of hep C who had compensated cirrhosis.

Glecaprevir/pibrentasvir (G/P) cured high rates of those with genotype 1 who failed a previous hep C cure attempt in a Phase II study.

This Hep story shows the power of never giving up, and the transformation that comes as a result.

The single-pill regimen would provide an eight-week ribavirin-free option for those with all viral genotypes who do not have cirrhosis.

The once-daily investigational hepatitis C virus (HCV) combination tablet will likely be approved in 2017.

AbbVie’s investigational daily, fixed-dose combination tablet performed very well among those with milder liver damage.

AbbVie’s investigational hepatitis C virus (HCV) treatment is poised for approval in 2017.

The investigational glecaprevir/pibrentasvir performed very well among the historically hard-to-treat group, including those with cirrhosis.

The standard treatment duration is 12 or 24 weeks.

The FDA grants breakthrough therapy designation to AbbVie's experimental hepatitis C regimen glecaprevir/pibrentasvir

AbbVie’s combination treatment of ABT-493 and ABT-530 has boasted high cure rates among all genotypes of hepatitis C virus.